News Sentiment

VRCA sentiment intelligence

Verrica Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.59 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.7% over one week, -0.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive -0.7% over four weeks
Fair value -77.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 43
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 13
Market source 8
dars.gov.et 6
GlobeNewswire 5
TradingKey 4
Stock Titan 3
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Earnings 31
Market update 28
Regulatory and legal 4
Balance sheet 3
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 68
Stock Titan Direct company coverage

Verrica starts Phase 3 common-warts trial with first U.S. patient

Verrica Pharmaceuticals announced the dosing of the first U.S. patient in its COVE-3 Phase 3 clinical trial for YCANTH (VP-102) for the treatment of common warts. This marks the second pivotal trial in its global Phase 3 program, with its Japanese partner Torii Pharmaceutical als

Tone
Positive 74/100
Event
Market update
Published
22 Jun 2026 12:12
Source
Stock Titan
Market source Direct company coverage

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals has announced that the first U.S. patient has been dosed in its COVE-3 clinical trial, the second pivotal Phase 3 study for YCANTH® (VP-102) targeting common warts. This follows the dosing of the first Japanese patient by their partner, Torii Pharmaceutica

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 12:12
Source
Market source
Investing.com Direct company coverage

Verrica doses first U.S. patient in common warts trial

Verrica Pharmaceuticals Inc. has initiated its second Phase 3 clinical trial, COVE-3, for YCANTH (VP-102) to treat common warts, with the first U.S. patient dosed. Their Japanese partner, Torii Pharmaceutical, also dosed the first patient in Japan for the same study. YCANTH is al

Tone
Positive 67/100
Event
Market update
Published
22 Jun 2026 12:12
Source
Investing.com
GlobeNewswire Direct company coverage

Verrica Pharmaceuticals Announces First U.S. Patient Dosed

Verrica Pharmaceuticals announced that the first U.S. patient has been dosed in the COVE-3 clinical trial, part of its Phase 3 program evaluating YCANTH® (VP-102) for common warts. This follows their Japanese partner, Torii Pharmaceutical, dosing the first Japanese patient last w

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 11:39
Source
GlobeNewswire
TradingKey Direct company coverage

Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Verrica Pharmaceuticals Inc (VRCA) has an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $19.00, with a strong buy recommendation based on 6 analyst ratings. The company's expected revenue

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:08
Source
TradingKey
TradingKey Direct company coverage

Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis

Verrica Pharmaceuticals Inc (VRCA) has a current valuation score of 7.41, placing it 128th out of 157 in the Pharmaceuticals industry. The company's P/E ratio stands at -5.09, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B

Tone
Negative 39/100
Event
Market update
Published
18 Jun 2026 02:10
Source
TradingKey
TradingKey Direct company coverage

Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on Verrica Pharmaceuticals Inc (VRCA), specifically attempting to detail its revenue breakdown by business segments and regional contributions. However, the core message of the article is that the relevant financial data for such a breakdown h

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:39
Source
TradingKey
TradingKey Direct company coverage

Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Verrica Pharmaceuticals Inc (VRCA), noting its current price momentum score of 7.02 and its ranking within the Pharmaceuticals industry. It highlights that the stock is trading between a resistance level of 6.59 and a support level of

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 20:40
Source
TradingKey